Valuation: Sera Prognostics, Inc.

Market Cap 80.28M 70.15M 64.73M 59.67M 112M 7.73B 115M 774M 304M 3.79B 301M 295M 13.03B P/E 2026 *
-3.13x
P/E 2027 * -3.66x
Enterprise Value 80.28M 70.15M 64.73M 59.67M 112M 7.73B 115M 774M 304M 3.79B 301M 295M 13.03B EV / Sales 2026 *
221x
EV / Sales 2027 * 30x
Free-Float
86.06%
Yield 2026 *
-
Yield 2027 * -
1 day-6.82%
1 week+4.06%
Current month+12.64%
1 month+17.14%
3 months-10.87%
6 months-43.99%
Current year-30.51%
1 week 1.9
Extreme 1.902
2.3
1 month 1.72
Extreme 1.725
2.3
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
13.51
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 39 06/06/2023
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 74 19/04/2011
Chairman 58 07/06/2023
Director/Board Member 59 31/10/2011
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Director

61,416 0.1608%
10/07/26 Free

Director

61,867 0.1620%
10/07/26 Free

Director

110,182 0.2885%
Change 5-day change 1-year change 3-year change Capi.($)
-6.82%+4.06%-29.79%-37.12% 80.28M
+0.46%+0.72%+14.15%+17.70% 23.39B
-2.15%+0.56%+24.96% - 17.69B
-4.88%-2.00%+8.42%-31.79% 3.27B
-12.13%-35.82%+23.10%-2.75% 2.46B
-1.71%-1.25%-33.17%-43.90% 1.87B
-13.76%-16.34%+107.95%+140.79% 1.79B
-1.01%-9.03%-40.90% - 1.52B
-5.03%-11.10%-9.28%+1.42% 1.49B
-3.50%-8.19%-17.19%-11.72% 1.25B
Average -5.05%-5.25%+4.82%+4.08% 5.48B
Weighted average by Cap. -2.10%-1.66%+16.20%+12.85%

Financials

2026 *2027 *
Net sales 362K 317K 292K 269K 508K 34.91M 519K 3.49M 1.37M 17.1M 1.36M 1.33M 58.86M 2.68M 2.34M 2.16M 1.99M 3.75M 258M 3.83M 25.78M 10.14M 126M 10.05M 9.83M 434M
Net income -33.26M -29.07M -26.82M -24.72M -46.6M -3.2B -47.63M -321M -126M -1.57B -125M -122M -5.4B -29.98M -26.2M -24.18M -22.28M -42M -2.89B -42.93M -289M -114M -1.41B -113M -110M -4.87B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
17/07/26 US$2.050 -6.82% 19,541
16/07/26 US$2.200 +1.85% 16,215
15/07/26 US$2.160 +9.09% 77,638
14/07/26 US$1.980 +3.13% 52,237
13/07/26 US$1.920 -2.54% 31,149
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.050USD
Average target price
5.500USD
Spread / Average Target
+168.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock